Senseonics Holdings (SENS) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Senseonics Holdings, Inc. Reports Fourth Quarter 2016 Financial Results
February 23, 2017 4:17 PM ESTGERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-MKT: SENS), a medical technology company focused on the development and commercialization of Eversense®, a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today reported financial results for the fourth quarter and full year ended December 31, 2016.
RECENT HIGHLIGHTS & ACCOMPLISHMENTS:
Submitted pre-market approval (PMA) for Eversense® to the U.S. Food and Drug Administration (FDA) in October 2016 Presented full Precise II U.S. Pivotal Trial results at the 16th Annual Diabetes Technology Meeting in Bethesda, Maryland in November... More